Gland’s Q4 Ebitda missed expectations by 40-45%, owing to Penem plant shutdowns, tender seasonality in the RoW business, and negative operating leverage due to lower topline/investments for the business. Despite FY23 being a wash-out year with overall revenue decline of 18%, visibility on growth normalization remains poor given increasing competitive intensity in key products (Enoxaparin/Heparin), lower revenue accretion from new launches and inventory rationalisation being done by customers. Analysts of IIFL Securities downgrade FY24/25 Ebitda by 17/14% on an exCenexi basis and overall EPS by 25/15% owing to multiple headwinds.
Gland is at best a 10-12% organic growth story…:
Post Cenexi acquisition, Gland’s revenue exposure to DMs will increase to ~80%; analysts of IIFL Securities believe DMs portfolio can at best grow at ~10% Cagr, given increasing competitive intensity in Injectables segment and declining revenue contribution from new product launches (3% in FY23 vs 10% in FY20/21). While RoW/India business can potentially grow at ~20% Cagr driven by MS gains in South-East Asia and ramp-up in China, analysts of IIFL Securities believe Gland’s overall organic revenue can grow only ~10-12% Cagr.
…assuming some headwinds don’t materialise:
Gland has seen incremental Chinese competition in Enoxaparin/Heparin and its top-10/30 products declined 20-25% YoY in FY23, per Exports data. Incrementally, Gland has lost one customer to whom it was supplying 14-15 products, while another customer (likely Athenex) that went bankrupt contributed Rs2bn revenue in FY23 (6% of overall revenue). Although mgmt expects limited impact from these customer discontinuations, there remains a downside risk to our organic growth assumption of 7% for FY24.
Cenexi acquisition to dilute Gland’s margin profile and analysts of IIFL Securities estimates assume Cenexi’s Ebitda margins to improve from 7.5/13.5% in H2CY22/CY22 to 15% by FY26, led by Gland’s initiatives to in-source manufacturing to India facilities and cost optimisation program. Although Gland’s overall margins will contract to 24-25% post Cenexi acquisition, our assumptions imply 29-30% margins for the base biz.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.